emerging bispecifics myeloma patients should know about | dr. joshua richter | the patient story
Published 2 years ago • 738 plays • Length 21:02Download video MP4
Download video MP3
Similar videos
-
5:20
what are bispecifics in multiple myeloma? (for patients and caregivers) | dr. joshua richter
-
5:02
questions to ask my doctor about new myeloma treatments | dr. joshua richter | the patient story
-
6:18
what to expect with car t cell therapy and bispecifics in myeloma (2022) | dr. joshua richter
-
3:04
what are celmods in multiple myeloma (& when will they be available?) | dr. joshua richter
-
3:11
bispecific antibodies | joshua richter, md | ash 2022
-
12:01
what are bispecific antibodies? how they are revolutionizing multiple myeloma treatment!
-
2:18
t cell re-direction therapy | joshua richter, md | eha 2022
-
8:56
myeloma research | car-t cell & bispecifics study updates
-
3:56
oncologists share why they pursued medicine | the doctor story (multiple myeloma)
-
4:09
what myeloma patients should know about treatment monitoring
-
2:01
dr. joshua richter discusses multiple myeloma clinical trials
-
4:17
evaluating the safety and efficacy of elranatamab in multiple myeloma
-
2:25
cevostamab in rrmm patients: camma 2 study results | joshua richter, md | eha 2024
-
2:35
defining the myeloma patient role in their care
-
1:28
regeneron bispecific antibody targeting bcma update | joshua richter, md | ash 2021
-
1:14
prevention & monitoring of infections in patients with multiple myeloma treated with immunotherapies
-
57:58
how often should mrd testing occur during remission (and an mrd overview) with dr. joshua richter
-
53:12
msbi dom grand rounds
-
2:06
safety & efficacy of cevostamab in patients with heavily pre-treated r/r multiple myeloma